Board Deck

Fictional Board Deck (Q2 Close – July Board Meeting)

Startup Name: *NimbusFlow*

Vertical: B2B SaaS — Workflow Automation for Regulated Industries

Stage: Series A | Targeting Series B EOY

Slide 1: Executive Summary

• **Q2 Revenue:** \$4.8M ARR (+42% QoQ)

• Burn Rate: \$650K/month → 8.5 months runway

• Strategic Client Signed: Lexan Health (\$1.2M ACV, 3-year deal)

• Series B Goal: \$10M ARR by EOY • **Team:** 57 FTEs (+9 this quarter)

• New Executive Hire: Priya Desai, CFO (ex-Gusto, ex-Benchmark-backed startup)

Slide 2: Revenue Highlights

• Net New ARR: +\$1.4M

• Expansion ARR: +\$420K

• Churn: 3.1% (1 enterprise client left due to missing enterprise SSO at scale)

• Sales Cycle: 94 days → improved from 112 days

• Big Deal: Lexan Health required 11 custom features (7 already in progress)

Slide 3: Product & Engineering

- PMF confirmed in mid-market healthcare & compliance workflows
- Infrastructure strain evident: backlog of stability tickets + latency spikes in Eastern region
- Custom roadmap divergence:
 - Lexan features = 28% of current Q3-Q4 capacity
 - Market-requested features slipping (e.g. Al audit trails, Jira/Asana integrations)

Slide 4: Product Roadmap Risks

Risk	Status	Mitigation Plan
Feature bloat from	🚨 High	Revisit contract SLAs /
Lexan		rescope mid-Q3

Infra instability	! Medium	Prioritize refactor sprint (was deprioritized Q2)
Tech debt blocking velocity	ligh High	Audit in progress; spike in prod incidents
Sales > Product alignment	! Medium	CRO-CPO planning offsite scheduled Q3 wk2
Series B metrics dilution	🖺 High	CFO leading margin + CAC review

Slide 5: Strategic Focus Areas (Q3–Q4)

1. Sustainable Velocity:

Refactor + hiring 2 senior engineers (backend & infra)

2. Roadmap Reconciliation:

Adjust mix: 70% core market features / 30% client-specific by October

3. Revenue Quality:

Tier deals by margin + repeatability with CFO; focus GTM on 3 verticals

- 4. Board + Investor Readiness:
 - o Rebuild Series B model w/ Priya
 - 4 targeted investor intros (Insight, Bessemer, Menlo, Scale)

Slide 6: Open Questions for Board

- What's our appetite for revenue risk vs. roadmap integrity?
- Should we re-scope Lexan contract post-funding?
- How should we present custom work to Series B VCs as signal or liability?
- How involved should Priya be in product/tech prioritization vs. pure finance?